📊 IBO Key Takeaways
Is Impact Biomedical Inc.. (IBO) a Good Investment?
Impact Biomedical faces an imminent liquidity crisis with only $20K in cash while burning $464K in operating losses per period against negligible $7K revenue. The company shows a fundamentally broken business model with operating margins exceeding -32,000% and a current ratio of 0.22x, indicating inability to meet near-term obligations.
Fundamentals are extremely weak: revenue is negligible and shrinking, margins are deeply negative, and operating cash burn is significant. With only ~$3K in cash and a sub-1.0 current ratio, liquidity risk is acute and likely requires external financing despite low leverage and positive equity.
Impact Biomedical Inc.. Key Strengths (IBO)
- Minimal debt burden with Debt/Equity ratio of 0.00x reduces insolvency risk from leverage
- Positive stockholders' equity of $11.5M provides some remaining asset backing
- Slight improvement in net loss metrics YoY (-0.3% reduction in net losses suggests marginal operational efficiency gains)
- No long-term debt (Debt/Equity 0.00x)
- Positive shareholders’ equity vs liabilities
- YoY improvement in EPS/net income (less negative)
IBO Stock Risks: Impact Biomedical Inc.. Investment Risks
- Critical liquidity crisis: $20K cash with $2.4M liabilities and current ratio of 0.22x indicates imminent insolvency
- Revenue collapse of 36% YoY to only $7K coupled with $2.3M operating losses signals complete operational failure
- Negative operating cash flow of $464K per period suggests cash runway exhaustion within weeks at current burn rate
- Company requires immediate dilutive financing or revenue generation to avoid bankruptcy
- Negative interest coverage of -2.9x indicates inability to service any debt obligations
- Severe liquidity shortfall (cash ~$3K, current ratio 0.35x)
- Persistent heavy losses and negative margins with minimal revenue
- High likelihood of dilution/going-concern risk to fund operations
Key Metrics to Watch
- Cash position and burn rate (critical - company may be insolvent within 1-2 quarters)
- Quarterly revenue trends (must show immediate reversal from $7K base to demonstrate viability)
- Operating cash flow improvement (currently -$464K and unsustainable)
- Cash & equivalents
- Operating cash flow
Impact Biomedical Inc.. (IBO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IBO Profit Margin, ROE & Profitability Analysis
IBO vs Healthcare Sector: How Impact Biomedical Inc.. Compares
How Impact Biomedical Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Impact Biomedical Inc.. Stock Overvalued? IBO Valuation Analysis 2026
Based on fundamental analysis, Impact Biomedical Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Impact Biomedical Inc.. Balance Sheet: IBO Debt, Cash & Liquidity
IBO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Impact Biomedical Inc..'s revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-2.30 indicates the company is currently unprofitable.
IBO Revenue Growth, EPS Growth & YoY Performance
IBO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.0K | -$1.3M | $-0.02 |
| Q3 2025 | $18.0K | -$1.5M | $0.03 |
| Q2 2025 | $7.0K | -$889.0K | $-0.09 |
| Q3 2023 | $50.0K | -$1.2M | $-0.02 |
| Q2 2023 | $50.0K | -$799.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Impact Biomedical Inc.. Dividends, Buybacks & Capital Allocation
IBO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Impact Biomedical Inc.. (CIK: 0001834105)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBO
What is the AI rating for IBO?
Impact Biomedical Inc.. (IBO) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBO's key strengths?
Claude: Minimal debt burden with Debt/Equity ratio of 0.00x reduces insolvency risk from leverage. Positive stockholders' equity of $11.5M provides some remaining asset backing. ChatGPT: No long-term debt (Debt/Equity 0.00x). Positive shareholders’ equity vs liabilities.
What are the risks of investing in IBO?
Claude: Critical liquidity crisis: $20K cash with $2.4M liabilities and current ratio of 0.22x indicates imminent insolvency. Revenue collapse of 36% YoY to only $7K coupled with $2.3M operating losses signals complete operational failure. ChatGPT: Severe liquidity shortfall (cash ~$3K, current ratio 0.35x). Persistent heavy losses and negative margins with minimal revenue.
What is IBO's revenue and growth?
Impact Biomedical Inc.. reported revenue of $7.0K.
Does IBO pay dividends?
Impact Biomedical Inc.. does not currently pay dividends.
Where can I find IBO SEC filings?
Official SEC filings for Impact Biomedical Inc.. (CIK: 0001834105) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBO's EPS?
Impact Biomedical Inc.. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IBO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Impact Biomedical Inc.. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IBO stock overvalued or undervalued?
Valuation metrics for IBO: ROE of -19.9% (sector avg: 15%), net margin of -32,671.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IBO's AI grade for 2026?
Our dual AI analysis gives Impact Biomedical Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBO's free cash flow?
Impact Biomedical Inc..'s operating cash flow is $-464.0K, with capital expenditures of N/A. FCF margin is -6,628.6%.
How does IBO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32,671.4% (avg: 12%), ROE -19.9% (avg: 15%), current ratio 0.22 (avg: 2).